Adbiron 250mg Tablet

Adbiron 250mg tablet is an anticancer medication used in the treatment of primarily prostate cancer in men. It contains Abiraterone Acetate as an active ingredient. The medicine works by inhibiting the enzyme which is responsible for the growth of cancer cells in the body. Doctors mostly suggest this hormonal therapy, specifically a type of anti-androgen therapy, also used in chemotherapy drug a form of targeted therapy in the same category as protein kinase inhibitors.

Prostate cancer

Adbiron 250mg tablet cause common as well as severe side effects, as it affects hormone level in the body, visit the doctor if the symptoms persist. Common side effects include:
● High blood pressure
● Urinary tract infection
● Edema (swelling)
● Vomiting
● Fatigue
● Anemia
● Hot flashes
● Headache
● Joint swelling

Doctor prescription is necessary for using Adbiron 250mg tablet. The medication should be taken on an empty stomach, either one hour before or two hours after the meal. Take it on a daily basis without skipping a single dose to increase the effectiveness of the treatment. Taking it in the wrong way or taking too much can cause very serious side effects. Consult the doctor to determine the correct dose and duration suitable for the condition.

Adbiron 250mg tablet work by restrict the protein (enzyme) CYP17 which is responsible for the growth of abnormal cancer cells in the body and is important for the production of androgen like testosterone. By reducing androgen production, the medicine helps slow the growth of prostate cancer that depends on testosterone.

• Thakur, A., Roy, A., Ghosh, A., Chhabra, M., & Banerjee, S. (2018). Abiraterone acetate in the treatment of prostate cancer. Biomedicine & Pharmacotherapy, 101, 211-218.
• Logothetis, C. J., Efstathiou, E., Manuguid, F., & Kirkpatrick, P. (2011). Abiraterone acetate. Nature Reviews Drug Discovery, 10(8), 573.
• Scott, L. J. (2017). Abiraterone acetate: a review in metastatic castration-resistant prostrate cancer. Drugs, 77(14), 1565-1576.
• Attard, G., Reid, A. H., A'Hern, R., Parker, C., Oommen, N. B., Folkerd, E., ... & de Bono, J. S. (2009). Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. Journal of clinical oncology, 27(23), 3742-3748.